The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo
Open accessAbstract
The BCL6 transcriptional repressor is the most frequently involved oncogene in diffuse large B cell lymphoma (DLBCL). We combined computer-aided drug design with functional assays to identify low-molecular-weight compounds that bind to the corepressor binding groove of the BCL6 BTB domain. One such compound disrupted BCL6/corepressor complexes in vitro and in vivo, and was observed by X-ray crystallography and NMR to bind the critical site within the BTB groove. This compound could induce expression of BCL6 target genes and kill BCL6-positive DLBCL cell lines. In xenotransplantation experiments, the compound was nontoxic and potently suppressed DLBCL tumors in vivo. The compound also killed primary DLBCLs from human patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several peptide and small molecule inhibitors targeting BCL6 have shown efficacy in vivo, but only at high concentrations, which has limited their translation into clinical therapeutic agents13,14.”
From Small-molecule-induced polymerization triggers degradation of BCL6 (2020) · cites this paper as [13]
In the citing paper
“BCL6 is a promising drug target for non-Hodgkin lymphomas including diffuse large B cell lymphoma (DLBCL)13,14 and follicular lymphoma15.”
From Small-molecule-induced polymerization triggers degradation of BCL6 (2020) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Berman, H. M. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.1.235 · Cited by 40,196
Coot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
The PyMOL Molecular Graphics System
DeLano, W. L. (2002) · Medical Entomology and Zoology · Cited by 18,147
Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination
Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse‐Kunstleve, R. W., Jiang, J., Kuszewski, J. J., Nilges, M., Pannu, N., et al. (1998) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444998003254 · Cited by 15,723
Refinement of Macromolecular Structures by the Maximum-Likelihood Method
Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,796
All-Atom Empirical Potential for Molecular Modeling and Dynamics Studies of Proteins
MacKerell, A. D., Bashford, D., Bellott, M., Dunbrack, R. L., Evanseck, J. D., Field, M. J., Fischer, S., Gao, J., Guo, H., Ha, S., et al. (1998) · The Journal of Physical Chemistry B · doi:10.1021/jp973084f · Cited by 14,429
Self-citationCHARMM: A program for macromolecular energy, minimization, and dynamics calculations
Brooks, B., Bruccoleri, R., Olafson, B. D., States, D., Swaminathan, S., & Karplus, M. (1983) · Journal of Computational Chemistry · doi:10.1002/jcc.540040211 · Cited by 13,736
Drug-like properties and the causes of poor solubility and poor permeability
Lipinski, C. A. (2000) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/s1056-8719(00)00107-6 · Cited by 3,776
A geometric approach to macromolecule-ligand interactions
Kuntz, I. D., Blaney, J. M., Oatley, S. J., Langridge, R., & Ferrin, T. E. (1982) · Journal of Molecular Biology · doi:10.1016/0022-2836(82)90153-x · Cited by 2,287
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 300
Chalcones: Potential Chemotherapeutic Compounds and Educational Tools for Closing the Loop in STEM
Russell, A. E., & Gines, B. R. (2023) · Accounts of Chemical Research · doi:10.1021/acs.accounts.2c00583 · Cited by 9
Fan, L., Li, L., Zhou, Y., & Li, J. (2017) · Journal of Hematology · doi:10.14740/jh320w · Cited by 9
Pathways towards indolent B-cell lymphoma — Etiology and therapeutic strategies
van den Brand, M., Scheijen, B., Hess, C. J., van Krieken, J. H., & Groenen, P. J. T. A. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.08.002 · Cited by 9
Omics Studies in Hemoglobinopathies
Katsantoni, E. Z. (2019) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-019-00386-1 · Cited by 9
Marullo, R., Rutherford, S. C., Leonard, J. P., & Cerchietti, L. C. A. (2016) · Cell Cycle · doi:10.1080/15384101.2016.1207839 · Cited by 9
Self-citationYu, X., Liao, X., Zhang, J., Wang, H., Li, X., Lu, J., Zhou, H., Wu, M., Jin, Y., Zhu, X. J., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01237 · Cited by 9
Self-citationRecent progress in targeting cancer
Demidenko, Z. N., & McCubrey, J. A. (2011) · Aging · doi:10.18632/aging.100421 · Cited by 8
Pierrat, O. A., Liu, M., Collie, G. W., Shetty, K. N., Rodrigues, M. J., Bihan, Y. L., Gunnell, E. A., McAndrew, C., Stubbs, M., Rowlands, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-23264-z · Cited by 8
Increased slow dynamics defines ligandability of BTB domains
Kharchenko, V., Linhares, B. M., Borregard, M., Czaban, I., Grembecka, J. E., Jaremko, M., Cierpicki, T., & Jaremko, Ł. (2022) · Nature Communications · doi:10.1038/s41467-022-34599-6 · Cited by 8
Karimi, S., Shahabi, F., Mubarak, S. M. H., Arjmandi, H., Hashemi, Z. S., Pourzardosht, N., Zakeri, A., Mahboobi, M., Jahangiri, A., Rahbar, M. R., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-25587-3 · Cited by 8
Evaluation of Rhodanine Indolinones as AANAT Inhibitors
Hagemeister, M., Hamilton, L. J., Wandrey, N., Hill, M., Mounce, E., Mosel, N., Lytle, K., Redinger, M., Boley, J., Fancher, N., et al. (2023) · ChemMedChem · doi:10.1002/cmdc.202300567 · Cited by 8
Gluing Proteins for Targeted Degradation
Naito, M., & Murata, S. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.12.020 · Cited by 8
Granadino‐Roldán, J. M., Obiol‐Pardo, C., Pinto, M., Garzón‐Ruiz, A., & Rubio, J. (2014) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2014.04.003 · Cited by 8
Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma
Waibel, M., Gregory, G. P., Shortt, J., & Johnstone, R. W. (2014) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000045 · Cited by 8
Gene Expression Profiling in Non-Hodgkin Lymphomas
Song, J. Y., Yu, J., & Chan, W. C. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-13150-4_4 · Cited by 8
Computational approaches for the design of protein–protein interaction inhibitors
Yu, W., Guvench, O., & MacKerell, A. D. (2013) · doi:10.4155/ebo.13.141 · Cited by 8
Self-citationThe ZBTB family in cardiac development and diseases
Xiang, X., Mao, J., Tang, D., Huang, H., & Tang, H. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152026 · Cited by 7
Room temperature catalyst-free Knoevenagel condensation: facile access to isatinylidenerhodanines
Xue, F., MacKerell, A. D., Heinzl, G. A., & Hom, K. (2013) · Tetrahedron Letters · doi:10.1016/j.tetlet.2013.01.069 · Cited by 7
Self-citationEmerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma
Janakiram, M., Thirukonda, V. K., Sullivan, M., & Petrich, A. M. (2012) · Current Treatment Options in Oncology · doi:10.1007/s11864-011-0178-9 · Cited by 7
Structural basis of Apt48 inhibition of the BCL6 BTB domain
Zacharchenko, T., Kalverda, A. P., & Wright, S. C. (2021) · Structure · doi:10.1016/j.str.2021.10.010 · Cited by 7
Luo, H., Schmidt, J. A., Lee, Y.-S., Oltz, E. M., & Payton, J. E. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1190973 · Cited by 7
Kikuchi, H., Higuchi, T., Hashida, Y., Taniguchi, A., Kamioka, M., Taguchi, T., Yokoyama, A., Murakami, I., Fujieda, M., & Daibata, M. (2018) · Oncotarget · doi:10.18632/oncotarget.26060 · Cited by 7
Transcriptional repressors, corepressors and chromatin modifying enzymes in T cell development
Shapiro, M. J., & Shapiro, V. S. (2010) · Cytokine · doi:10.1016/j.cyto.2010.11.013 · Cited by 7
Chen, X., Wang, Y., Huang, X., Geng, S., Li, C. L., Zeng, L., Huang, L., Du, X., Weng, J., & Lai, P. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109746 · Cited by 6
Anticancer Therapy SMRT-ens Up: Targeting the BCL6-SMRT Interaction in B Cell Lymphoma
Compton, L. A., & Hiebert, S. W. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.012 · Cited by 6
Genetic and Molecular Targets in Lymphoma: Implications for Prognosis and Treatment
Bachegowda, L., & Barta, S. K. (2014) · Future Oncology · doi:10.2217/fon.14.112 · Cited by 6
Chung, C. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155219895079 · Cited by 6
BCL6 confers resistance to HDAC inhibitors in DLBCL
Gao, F., Zhang, Y., Li, Q., Rong, R., He, L., He, L., Li, B., & Zhuang, W. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116466 · Cited by 5
Xing, Y., Tan, C., Liu, Z., Liu, Y., Liu, S., Wang, G., & Zhong, Y. (2025) · Journal of Natural Medicines · doi:10.1007/s11418-024-01873-4 · Cited by 5
Mouse models of diffuse large B cell lymphoma
Tabatabai, A., Arora, A., Höfmann, S., Jauch, M., von Tresckow, B., Hansen, J., Flümann, R., Jachimowicz, R. D., Klein, S., Reinhardt, H. C., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1313371 · Cited by 6
Takahara, T., Matsuo, K., Seto, M., Nakamura, S., & Tsuzuki, S. (2016) · Cancer Science · doi:10.1111/cas.13057 · Cited by 5
Sausville, E. A. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-385471-1.00030-1 · Cited by 5
Prospects of Modulating Protein–Protein Interactions
Zhong, S., Oashi, T., Yu, W., Shapiro, P., & MacKerell, A. D. (2012) · Wiley eBooks · doi:10.1002/9783527645947.ch15 · Cited by 5
Self-citationUsing Cytogenetic Rearrangements for Cancer Prognosis and Treatment (Pharmacogenetics)
Li, M. M., Ewton, A. A., & Smith, J. L. (2013) · Current Genetic Medicine Reports · doi:10.1007/s40142-013-0011-9 · Cited by 4
Clinical Controversies of Double-Hit Lymphoma
Stephens, D. M., & Sweetenham, J. W. (2015) · American Journal of Hematology / Oncology® · Cited by 4
Modelling approaches in tumor microenvironment.
Crespo, I., Coukos, G., Doucey, M., & Xénarios, I. (2018) · doi:10.35841/cancer-immunology.1.1.26-40 · Cited by 4
Ligand-free copper-mediated N-arylation of spirocyclic lactams
Yang, W., Coutinho, A. L., ABDEL‐HAFEZ, A. A., Jiang, C., & Xue, F. (2015) · Tetrahedron Letters · doi:10.1016/j.tetlet.2015.08.051 · Cited by 4
B-cell lymphoma 6 in breast cancer: molecular mechanisms and clinical significance
Louwen, F., Ritter, A., Kreis, N., Hoock, S. C., Solbach, C., & Yuan, J. (2025) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2025.2521319 · Cited by 4
Jardin, F., & Tilly, H. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-408-1_11 · Cited by 3
Role of Biomarkers in Personalized Medicine
Islam, S. U., Ahmed, M. B., Ahsan, H., & Lee, Y. S. (2022) · Springer eBooks · doi:10.1007/978-981-16-5759-7_10 · Cited by 4
Specific radiation damage to halogenated inhibitors and ligands in protein–ligand crystal structures
Rodrigues, M. J., Cabry, M., Collie, G. W., Carter, M. W., McAndrew, C., Owen, R. L., Bellenie, B. R., Bihan, Y. L., & van Montfort, R. L. M. (2024) · Journal of Applied Crystallography · doi:10.1107/s1600576724010549 · Cited by 3
Kraaijeveld, R., Hesselink, D. A., Dieterich, M., van den Bosch, T. P. P., Heidt, S., & Baan, C. C. (2025) · Human Immunology · doi:10.1016/j.humimm.2025.111242 · Cited by 3
Pathology and Molecular Pathogenesis of DLBCL and Related Entities
Pasqualucci, L., & Ott, G. (2018) · Methods in molecular biology · doi:10.1007/978-3-030-00362-3_2 · Cited by 4
Xing, Y., Guo, W., Wu, M., Xie, J., Huang, D., Hu, P., Zhou, M., Zhang, L., Zhang, Q., Wang, P., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-820765/v1 · Cited by 3
Gil, A. M., Zegarra-Ruiz, D. F., Wu, W.-J. H., Norwood, K., Assié, A., Samuel, B. S., Major, A. M., Diehl, G. E., & Hill, A. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-12448-y · Cited by 2
Diffuse Large B-Cell Lymphoma: Recognition of Markers for Targeted Therapy
Tomás‐Roca, L., Rodríguez, M., Alonso‐Alonso, R., Rodríguez-Pinilla, S. M., & Piris, M. A. (2021) · Hemato · doi:10.3390/hemato2020017 · Cited by 2
How CBX proteins regulate normal and leukemic blood cells
de Groot, A. P., & de Haan, G. (2024) · FEBS Letters · doi:10.1002/1873-3468.14839 · Cited by 4
A Small-Molecule BCL6 Inhibitor as an Anti-Proliferative Agent for Diffuse Large B-Cell Lymphoma
Xing, Y., Guo, W., Wu, M., Xie, J., Huang, D., Hu, P., Zhou, M., Zhang, L., Zhong, Y., Liu, M., et al. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0830 · Cited by 2
Luo, W., Tripathi, M. K., Liu, Q., Chen, L., Cowan, R. W., Daniel, J. M., Yan, C. W., Richmond, A. J., & Reynolds, A. B. (2025) · Open Biology · doi:10.1098/rsob.240329 · Cited by 2
The importance of radiotherapy on diffuse large B cell lymphoma treatment: a current review
Mendes, F., Domingues, C., Teixo, R. J., Abrantes, A. M., Gonçalves, A. C., Nobre-Góis, I., Jacobetty, M., Sarmento‐Ribeiro, A. B., Botelho, M. F., & Rosa, M. S. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9581-1 · Cited by 2
Genetic mutations in chronic myelogenous leukemia
Berman, E. (2012) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32834ff4f7 · Cited by 2
Zeisig, B. B., & So, C. W. E. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.07.014 · Cited by 2
Lennerz, J. K. (2014) · Oncotarget · doi:10.18632/oncotarget.2827 · Cited by 2
BCL6 inhibition: a promising approach to prevent germinal center-driven allo-immune responses
Kraaijeveld, R., Hesselink, D. A., Steines, L., Heidt, S., & Baan, C. C. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1667185 · Cited by 2
Zheng, H., Yang, L., Zhu, P., & Lin, Y. (2025) · Human Mutation · doi:10.1155/humu/7388320 · Cited by 1
Discovery of pyrrolopyrimidinone inhibitors of the BCL6-SMRT corepressor interaction
Watson, I. D. G., Morin, J. A., Subramanian, P. R., Chau, A. M., Prakesch, M. A., Wilson, B. J., Morshed, M. M., Joseph, B. B., Uehling, D., Poda, G. I., et al. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118575 · Cited by 1
Self-citation(2010) · Nature Biotechnology · doi:10.1038/nbt0610-566 · Cited by 1
COROBEA, A. B., Evsei, A., Rosianu, C. G., Gheorghe, M., BIRCEANU, G., Copcă, N., Sajin, M., & Lupu, A. R. (2018) · Archives of the Balkan Medical Union · doi:10.31688/abmu.2018.53.2.09 · Cited by 1
The DNA binding protein BCL6 regulates NFκB-controlled endothelial inflammatory gene expressionPreprint
Acevedo, A. F., Mack, J. J., & Valenzuela, N. M. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.11.03.514942 · Cited by 1
Genomic Analysis of B-Cell Lymphomas
Davis, R. E. (2013) · Humana Press eBooks · doi:10.1007/978-1-62703-408-1_2
Eradicating leukemia stem cells
Cain, C. (2011) · Science-Business eXchange · doi:10.1038/scibx.2011.1056
Targeting primary mediastinal B-cell lymphoma
Wagner, S. D. (2014) · Oncotarget · doi:10.18632/oncotarget.2351
van Krieken, J. H. (2010) · Journal of Hematopathology · doi:10.1007/s12308-010-0069-1
Molecular Pathogenesis of Aggressive B-cell Lymphomas
Juszczyński, P., & Warzocha, K. (2012) · Principles and practice · doi:10.1007/978-3-642-29467-9_3
Potential New Drugs in Lymphoma
Delforoush, M. (2016) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
Aberrant Transcriptional Programming in Blood Cancers
Bonifer, C., Cockerill, P. N., & Ptasinska, A. (2015) · Springer eBooks · doi:10.1007/978-3-319-19983-2_22
Snapshots of CD4+ T cell plasticity in the pathogenesis of allergic asthma
Chae, W., & Bothwell, A. L. M. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.08.19
Une approche raisonnée du traitement des lymphomes diffus à grandes cellules
Larsen, C. (2010) · Bulletin du Cancer · doi:10.1684/bdc.2010.1152
Novel BCL6 Inhibitor (FX1): Advances in Diffuse Large B-Cell Lymphomas (DLBCLs) Treatment
Hasan, M. K. (2017) · Biomedical Sciences · doi:10.11648/j.bs.20170302.12
DNA and Histone Methylation in Hematopoietic Malignancy
Kawabata, K. C., & Kitamura, T. (2017) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-59786-7_14
Thome, M. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.717967697.793467369
The Role of BCL6 in Glioblastoma
Jones, N. M. (2018) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17072567
Dimitrova, P. A., & Shivarov, V. S. (2013) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.718085329.793486454
(2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3193
Wu, M., Zhang, L., Guo, W., Lv, S., Jin, W., Zhu, S., Chen, H., Jian, S., Liu, L., Xing, Y., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2936278/v1
Xing, Y., Guo, W., Wu, M. Y., Xie, J., Huang, D., Hu, P., Zhou, M., Zhang, Q., Wang, P., Wang, X., et al. (2024) · doi:10.22541/au.170667314.42007148/v1
Cai, Z., You, S., Liu, Z., Song, P., Zhao, F., An, J., Ding, Y., He, B., & Zou, M. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06597-7
Warp and Woof of Drug Designing and Development: An In-Silico Approach
Chauhan, M., Gupta, V., Arora, A., Kaur, G., Bansal, P., & Sharma, R. (2024) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815223019124010014
Wu, M., Zhang, L., Guo, W., Lv, S., Jin, W., Zhu, S., Chen, H., Jian, S., Liu, L., Xing, Y., et al. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101644
Small Molecule Inhibitors Targeting Protein–Protein Interactions in the BCL Protein
Zhu, W., He, Y., Chen, G., & Zhu, D. (2025) · Wiley eBooks · doi:10.1002/9783527845828.ch12
Mamai, A., Morshed, M. M., Prakesch, M. A., Poda, G. I., Pandiaraju, S., Chau, A. M., Watson, I. D. G., Joseph, B., Wilson, B., Morin, J. A., et al. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130471
Self-citationProtein-protein interaction inhibitors in cancer
Hardcastle, I. R., Goujon-Ricci, J., & Thompson, W. I. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00067-4
Oncogenic Role of BCL6 Rearrangement: A Focus on Follicular and Marginal Zone Lymphomas
Pâris, L., Chassagne-Clement, C., Bachy, E., Ghesquières, H., Mauduit, C., Pissaloux, D., Trécourt, A., Laurent, C., Beillard, E. J., Traverse‐Glehen, A., et al. (2026) · Modern Pathology · doi:10.1016/j.modpat.2026.101055
Recent Advances in Chronic Myeloid Leukaemia (CML): Emerging Molecular and Immunotherapeutic Targets
Dai, J., Zheng, P., Liu, J., Cheng, L., Zheng, X. W., Chen, L., Jiang, J., & Zheng, Z. (2026) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl48912
BindingDB Entry 50007681: Achieving
BindingDB (2021) · UC San Diego · doi:10.7270/q2df6vk2
BindingDB (2023) · UC San Diego · doi:10.7270/q2r21585
BindingDB (2017) · UC San Diego · doi:10.7270/q2th8pjq
BindingDB Entry 50008540: Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of
BindingDB (2021) · UC San Diego · doi:10.7270/q2gf0xw8
Metadata
- Authors
- Cerchietti, L. C., Ghetu, A. F., Zhu, X., Da Silva, G. F., Zhong, S., Matthews, M., Bunting, K. L., Polo, J. M., Farès, C., Arrowsmith, C. H., Yang, S. N., Garcia, M., Coop, A., MacKerell, A. D., Privé, G. G., & Melnick, A.
- Affiliations
- Cornell University (US)
- University of Maryland, Baltimore (US)
- Albert Einstein College of Medicine (US)
- University of Toronto (CA)
- Corresponding author
- MacKerell, Alexander D.
- Privé, Gilbert G.
- Melnick, Ari
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-04
- Volume
- 17
- Issue
- 4
- Pages
- 400-411
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC2858395
- OpenAlex
- W2018796139
- Cited by
- 288
- References
- 53
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 9 · 2023: 9 · 2022: 13 · 2021: 12 · 2020: 20 · 2019: 19 · 2018: 16 · 2017: 15 · 2016: 30 · 2015: 28 · 2014: 24 · 2013: 28 · 2012: 22
- FWCI
- 16.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Max Planck Digital Library (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, cc-by)
- Funders
- Canadian Cancer Society
- Leukemia and Lymphoma Society
- National Cancer Institute (R01 CA104348)
- National Institutes of Health (HL082670, CA107331, CA120215)
- University of Maryland Foundation Inc.
- Chemotherapy Foundation
- Samuel Waxman Cancer Research Foundation
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- BCL6, diffuse large B-cell lymphoma, small molecule inhibitors, BTB domain, transcriptional repressor, computer-aided drug design, xenotransplantation, oncogenes
- MeSH terms
- Animals, Cell Division, Cell Survival, Humans, Mice, Inbred C57BL, Models, Molecular, Protein Conformation, Proto-Oncogene Proteins, Repressor Proteins, Transcription, Genetic, Zinc Fingers, Lymphoma, Large B-Cell, Diffuse, Crystallography, X-Ray, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
